title: Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.
abstract: Patients with lower urinary tract symptoms and enlarged prostate were randomized to receive, in a double blind fashion, either Finasteride 5 mg/day or Dutasteride 0.5 mg/day for a period of 12 weeks. IPSS score, Qmax, and Quality of Life were assessed at the end of 0 and 12 week periods. Dutasteride significantly improved Qmax, reduced IPSS score, and improved Quality of Life as compared to Finasteride at the end of the 12-week period. Dutasteride with its inhibitory effects on type 1 and 2 5alpha-reductase, produces significantly better results than Finasteride.
authors.affiliation: Department of Urology, KLES Kidney Foundation, Belgaum, India. irravish@yahoo.com
authors.forename: I R
authors.initials: IR
authors.lastname: Ravish
authors.forename: R B
authors.initials: RB
authors.lastname: Nerli
authors.forename: S S
authors.initials: SS
authors.lastname: Amarkhed
mesh_terms: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids / Q000627:therapeutic use*; D004231:Diuresis; D004311:Double-Blind Method; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D016896:Treatment Outcome; D014570:Urologic Diseases / Q000188:drug therapy*
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D004791:Enzyme Inhibitors; D018120:Finasteride; D000068538:Dutasteride